Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10224	Companies
210789	Keywords
140751	Articles
111677	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 09/16/2025 at 12:00, 6 months 29 days ago

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
Moderna reports 8-fold increase in neutralizing antibodies with Spikevax 2025-2026 formula, reinforcing FDA approval. Clinical trial data supports efficacy against COVID-19 LP.8.1 variant

FDA Approval COVID-19 Vaccine Moderna Spikevax Neutralizing Antibodies
BRIEF

published on 09/02/2025 at 13:05, 7 months 13 days ago

Moderna to Present mRNA Therapeutics Data at 2025 ICIEM

MRNA Therapeutics Moderna Propionic Acidemia ICIEM Methylmalonic Acidemia
PRESS RELEASE

published on 09/02/2025 at 13:00, 7 months 13 days ago

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
Moderna, Inc. to present abstracts on mRNA therapeutics at the 2025 ICIEM including PA, MMA, and GSD1a programs in Kyoto, Japan. Company's first time presenting data for MMA and GSD1a

Moderna Inc. MRNA Therapeutics ICIEM Abstracts Kyoto Japan
BRIEF

published on 08/27/2025 at 19:29, 7 months 19 days ago

Moderna's Updated COVID-19 Vaccines Approved by U.S. FDA

FDA Approval COVID-19 Vaccine Moderna SARS-CoV-2 Variant Spikevax And MNEXSPIKE
PRESS RELEASE

published on 08/27/2025 at 19:24, 7 months 19 days ago

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
Moderna announces FDA approval for updated Spikevax® and mNEXSPIKE® COVID-19 vaccines targeting LP.8.1 variant to prevent severe outcomes. Vaccines available soon

FDA Approval Moderna COVID-19 Vaccines Spikevax MNEXSPIKE
BRIEF

published on 08/22/2025 at 15:30, 7 months 24 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine

COVID-19 Vaccine Moderna Health Canada Approval Canadian Manufacturing Biomanufacturing Leadership
PRESS RELEASE

published on 08/22/2025 at 15:25, 7 months 24 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Moderna's Spikevax COVID-19 vaccine for SARS-CoV-2 LP.8.1 variant authorized in Canada, with all 2025 doses produced domestically. Leadership in biomanufacturing highlighted

COVID-19 Vaccine Canada Moderna Spikevax Biomanufacturing
BRIEF

published on 08/21/2025 at 13:05, 7 months 25 days ago

Moderna to Participate in Major September 2025 Conferences

Investor Conferences MRNA Medicine Moderna Live Webcast Healthcare Presentation
PRESS RELEASE

published on 08/21/2025 at 13:00, 7 months 25 days ago

Moderna to Present at Upcoming Conferences in September 2025
Moderna, Inc. to participate in upcoming investor conferences. The company's innovative mRNA technology redefines medicine creation, focusing on infectious diseases, oncology, and more

Investor Conferences Healthcare COVID-19 Vaccine MRNA Technology Moderna
BRIEF

published on 08/01/2025 at 13:05, 8 months 14 days ago

Moderna's Q2 2025 Financial Results and Business Updates

Cost Management FDA Approvals Q2 2025 Revenue Moderna Financial Results Vaccine Sales

Accesswire

Published on 04/15/2026 at 23:00, 2 hours 43 minutes ago

EV Nickel Intersects 1.20% Nickel Over 9.80 Metres at Langmuir South
Published on 04/15/2026 at 22:30, 3 hours 13 minutes ago

Avant Brands Announces its Annual General and Special Meeting
Published on 04/15/2026 at 22:15, 3 hours 28 minutes ago

APPULSE CORPORATION (Listed on the TSX Venture Exchange - Symbol 'APL') - Reporting Results for the 2025 Fiscal Year and Adoption of Semi-annual Reporting
Published on 04/15/2026 at 22:00, 3 hours 43 minutes ago

NioCorp to Participate in Maxim Group's "Mining the Industrial Supply Chain" Conference on Apr. 21
Published on 04/15/2026 at 18:25, 7 hours 18 minutes ago

Sky Gold Reports on Private Placement and Announces Commencement of Drilling on the Evening Star Project, Walker Lane Trend, Nevada

View all ACCESSWIRE

EQS Group

Published on 04/15/2026 at 22:50, 2 hours 53 minutes ago

AIXTRON SE successfully placed EUR 450 million convertible bonds
Published on 04/15/2026 at 22:47, 2 hours 55 minutes ago

EQS-Adhoc: AIXTRON SE successfully placed EUR 450 million convertible bonds
Published on 04/15/2026 at 22:35, 3 hours 8 minutes ago

Gerresheimer: Broad Support from Creditors / Creditors agree to extend the due date / Sales process for Centor Inc. launched as planned
Published on 04/15/2026 at 22:23, 3 hours 19 minutes ago

EQS-Adhoc: Gerresheimer AG: Creditors agree to extend the due date for submitting the audited 2025 annual and consolidated financial statements
Published on 04/15/2026 at 21:05, 4 hours 38 minutes ago

EQS-Adhoc: Advanced Blockchain AG: Change in the Management Board

Les Echos

Published on 04/15/2026 at 20:12, 5 hours 31 minutes ago

Covivio - Q1 2026 activity : Strategic progress driving growth
Published on 04/15/2026 at 18:43, 6 hours 59 minutes ago

SFPI GROUP: publication des résultats 2025
Published on 04/15/2026 at 17:45, 7 hours 58 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2026
Published on 04/15/2026 at 07:30, 18 hours 13 minutes ago

Covivio Hotels - Revenues at end-March 2026 : +1.4% Revenue growth year-on-year
Published on 04/15/2026 at 07:30, 18 hours 13 minutes ago

Covivio is accelerating its expansion in the hotel sector with the acquisition of four hotels in Milan for €217 million

View all LES ECHOS COMFI WIRE